NICE to increase use of real-world evidence
04 March 2020
- NICE plans to use more data resources than RCTs this year for submissions
- MHRA already takes account of real-world studies, in order to facilitate their upcoming 150 day licensing commitments
- The utilisation of real world data will be key in tackling the funding and access issue surrounding NICE reimbursement
Click here to learn more
About SVMPharma
SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.
For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com
ref: FEB2020LN002